Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma

Jumpei Ito, Haruko Shima, Kyohei Inoue, Fumito Yamazaki, Hiroyuki Shimada

Research output: Contribution to journalArticle


Juvenile xanthogranuloma (JXG) is a generally benign, self-limited histiocytic disorder, which belongs to non-Langerhans cell histiocytoses (non-LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11-year-old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen-haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non-LCH.

Original languageEnglish
Article numbere27926
JournalPediatric Blood and Cancer
Issue number10
Publication statusPublished - 2019 Jan 1



  • allogeneic hematopoietic stem cell transplantation
  • haploidentical HSCT with posttransplant cyclophosphamide
  • juvenile xanthogranuloma
  • non-LCH

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this